全文获取类型
收费全文 | 1659篇 |
免费 | 105篇 |
出版年
2023年 | 13篇 |
2022年 | 12篇 |
2021年 | 56篇 |
2020年 | 36篇 |
2019年 | 41篇 |
2018年 | 68篇 |
2017年 | 73篇 |
2016年 | 60篇 |
2015年 | 84篇 |
2014年 | 95篇 |
2013年 | 142篇 |
2012年 | 116篇 |
2011年 | 138篇 |
2010年 | 101篇 |
2009年 | 47篇 |
2008年 | 73篇 |
2007年 | 58篇 |
2006年 | 58篇 |
2005年 | 35篇 |
2004年 | 37篇 |
2003年 | 21篇 |
2002年 | 28篇 |
2001年 | 12篇 |
2000年 | 9篇 |
1999年 | 2篇 |
1998年 | 13篇 |
1997年 | 11篇 |
1996年 | 2篇 |
1995年 | 5篇 |
1992年 | 3篇 |
1991年 | 5篇 |
1985年 | 4篇 |
1984年 | 3篇 |
1983年 | 3篇 |
1981年 | 4篇 |
1978年 | 3篇 |
1977年 | 3篇 |
1971年 | 2篇 |
1955年 | 29篇 |
1954年 | 77篇 |
1953年 | 42篇 |
1952年 | 27篇 |
1951年 | 20篇 |
1950年 | 56篇 |
1949年 | 12篇 |
1948年 | 5篇 |
1947年 | 3篇 |
1937年 | 1篇 |
1936年 | 1篇 |
1905年 | 1篇 |
排序方式: 共有1764条查询结果,搜索用时 46 毫秒
11.
12.
After cardiovascular diseases, infectious diseases are the second most common cause of death worldwide. Although these infections are caused mainly by viruses or bacteria, a systematically growing prevalence of human and animal opportunistic fungal infections is noticeable worldwide. More attention is being paid to this problem, especially due to the growing frequency of recalcitrant and recurrent mycoses. The latter are classically divided into superficial, which are the most common type, subcutaneous, and systemic. This work discusses opportunistic fungal pathogens without proven horizontal transmission between different animal species including humans and microsporidia as spore-forming unicellular parasites related to fungi; however, with a yet undetermined taxonomic position. The review also mentions aetiological agents, risk factors, epidemiology, geographical distribution, and finally symptoms characteristic for individual disease entities. This paper provides insight into fungal infections from a global perspective and simultaneously draws attention to emerging pathogens, whose prevalence is continuously increasing. Finally, this work also takes into consideration the correct nomenclature of fungal disease entities and the importance of secondary metabolites in the pathogenesis of fungal infections. 相似文献
13.
Daniel E. Adkins Renan P. Souza Karolina ?berg Shaunna L. Clark Joseph L. McClay Patrick F. Sullivan Edwin J. C. G. van den Oord 《PloS one》2013,8(2)
Only a subset of patients will typically respond to any given prescribed drug. The time it takes clinicians to declare a treatment ineffective leaves the patient in an impaired state and at unnecessary risk for adverse drug effects. Thus, diagnostic tests robustly predicting the most effective and safe medication for each patient prior to starting pharmacotherapy would have tremendous clinical value. In this article, we evaluated the use of genetic markers to estimate ancestry as a predictive component of such diagnostic tests. We first estimated each patient’s unique mosaic of ancestral backgrounds using genome-wide SNP data collected in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) (n = 765) and the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) (n = 1892). Next, we performed multiple regression analyses to estimate the predictive power of these ancestral dimensions. For 136/89 treatment-outcome combinations tested in CATIE/STAR*D, results indicated 1.67/1.84 times higher median test statistics than expected under the null hypothesis assuming no predictive power (p<0.01, both samples). Thus, ancestry showed robust and pervasive correlations with drug efficacy and side effects in both CATIE and STAR*D. Comparison of the marginal predictive power of MDS ancestral dimensions and self-reported race indicated significant improvements to model fit with the inclusion of MDS dimensions, but mixed evidence for self-reported race. Knowledge of each patient’s unique mosaic of ancestral backgrounds provides a potent immediate starting point for developing algorithms identifying the most effective and safe medication for a wide variety of drug-treatment response combinations. As relatively few new psychiatric drugs are currently under development, such personalized medicine offers a promising approach toward optimizing pharmacotherapy for psychiatric conditions. 相似文献
14.
Magdalena Czeredys ?ukasz Samluk Katarzyna Michalec Karolina Tu?odziecka Krzysztof Skowronek Katarzyna A. Na??cz 《PloS one》2013,8(12)
OCTN2 - the Organic Cation Transporter Novel family member 2 (SLC22A5) is known to be a xenobiotic/drug transporter. It transports as well carnitine - a compound necessary for oxidation of fatty acids and mutations of its gene cause primary carnitine deficiency. Octn2 regulation by protein kinase C (PKC) was studied in rat astrocytes - cells in which β-oxidation takes place in the brain. Activation of PKC with phorbol ester stimulated L-carnitine transport and increased cell surface presence of the transporter, although no PKC-specific phosphorylation of Octn2 could be detected. PKC activation resulted in an augmented Octn2 presence in cholesterol/sphingolipid-rich microdomains of plasma membrane (rafts) and increased co-precipitation of Octn2 with raft-proteins, caveolin-1 and flotillin-1. Deletion of potential caveolin-1 binding motifs pointed to amino acids 14–22 and 447–454 as the caveolin-1 binding sites within Octn2 sequence. A direct interaction of Octn2 with caveolin-1 in astrocytes upon PKC activation was detected by proximity ligation assay, while such an interaction was excluded in case of flotillin-1. Functioning of a multi-protein complex regulated by PKC has been postulated in rOctn2 trafficking to the cell surface, a process which could be important both under physiological conditions, when carnitine facilitates fatty acids catabolism and controls free Coenzyme A pool as well as in pathology, when transport of several drugs can induce secondary carnitine deficiency. 相似文献
15.
Jonas G. Barlind Linda K. Buckett Sharon G. Crosby Öjvind Davidsson Hans Emtenäs Anne Ertan Ulrik Jurva Malin Lemurell Pablo Morentin Gutierrez Karolina Nilsson Gavin O’Mahony Annika U. Petersson Alma Redzic Fredrik Wågberg Zhong-Qing Yuan 《Bioorganic & medicinal chemistry letters》2013,23(9):2721-2726
[Acyl CoA]monoacylglycerol acyltransferase 2 (MGAT2) is of interest as a target for therapeutic treatment of diabetes, obesity and other diseases which together constitute the metabolic syndrome. In this Letter we report our discovery and optimisation of a novel series of MGAT2 inhibitors. The development of the SAR of the series and a detailed discussion around some key parameters monitored and addressed during the lead generation phase will be given. The in vivo results from an oral lipid tolerance test (OLTT) using the MGAT2 inhibitor (S)-10, shows a significant reduction (68% inhibition relative to na?ve, p <0.01) in plasma triacylglycerol (TAG) concentration. 相似文献
16.
17.
18.
19.
20.
Szyrwiel Łukasz Shimura Mari Setner Bartosz Szewczuk Zbigniew Malec Katarzyna Malinka Wieslaw Brasun Justyna Pap József Sándor 《International journal of peptide research and therapeutics》2019,25(2):711-717
International Journal of Peptide Research and Therapeutics - Relations between structural modifiactions and SOD-like activity of four branched CuII-metallopeptides based on l-2,3-diaminopropionic... 相似文献